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Abstract
The tyrosine kinase inhibitor (TKI) imatinib has resulted in excellent responses in the major-
ity of Chronic Myeloid Leukaemia (CML) patients; however, resistance is observed in 20–
30% of patients. More recently, resistance to the second generation TKIs, nilotinib and
dasatinib, has also been observed albeit at a lower incidence. ABCB1 has previously been
implicated in TKI export and its overexpression linked to TKI resistance. In this study the
dynamics of nilotinib resistance was studied in CML cell lines with particular focus on
ABCB1 expression levels during development of resistance. Results revealed ABCB1 over-
expression is likely an important initiator of nilotinib resistance in vitro. ABCB1 overexpres-
sion was also observed in cell lines as an intermediate step during development of
resistance to imatinib and dasatinib in vitro. We conclude that ABCB1 overexpression may
provide an initial platform to facilitate development of additional mechanisms for resistance
to TKIs. This provides a rationale for investigating this phenomenon in patients undergoing
TKI therapy.
Introduction
Chronic myeloid leukemia (CML) is a malignant disorder of the blood stem cells characterized
by the presence of the Philadelphia chromosome which gives rise to the BCR-ABL tyrosine
kinase[1, 2]. Tyrosine kinase inhibitors (TKIs), such as imatinib[3], and the second generation
inhibitors nilotinib[4] and dasatinib[5], act by selectively binding to the BCR-ABL kinase
domain to inhibit kinase activity and subsequent downstream oncogenic signaling[6]. The
advent of TKIs resulted in significantly improved treatment outcomes for the majority of
patients with chronic phase(CP)-CML[7]; however, an estimated 20–30% of patients treated
with first line imatinib therapy will exhibit primary or secondary resistance[8, 9]. More
recently, resistance to second generation TKIs has also been observed[10, 11].
There are several overlapping modes of resistance to TKIs, which can be broadly classified
as BCR-ABL dependent and independent. BCR-ABL1 overexpression has been observed both
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in vitro[12–17] and in vivo[18–22] and presumably leads to an increase in the amount of active
BCR-ABL kinase within the cell rendering clinically achievable concentrations of TKI ineffec-
tive. The most common mode of secondary TKI resistance observed clinically is mutation to
key regions of the BCR-ABL kinase domain, which prevents TKI binding; up to 40% of resis-
tant patients develop mutations while on TKI therapy[23–25]. Dasatinib is a dual BCR-ABL/
Src family kinase (SFK) inhibitor whereas imatinib and nilotinib are not active against most
SFKs[26]. Accordingly, overexpression and activation of SFKs, such as LYN, are often observed
in imatinib and nilotinib resistant cells, both in vitro[27–32] and in vivo[28, 30, 32, 33].
Intracellular drug concentrations are dependent on numerous parameters including absorp-
tion, distribution, metabolism, excretion and toxicity (ADME-Tox). One of the major groups
of transporters involved in ADME-Tox is the ATP-Binding Cassette (ABC) superfamily. The
interaction of ABCB1 and ABCG2 with TKIs has been extensively reviewed with the consensus
indicating that ABCB1 is involved in TKI export at clinically relevant concentrations[34].
Overexpression of ABCB1 has also been implicated in resistance to imatinib, nilotinib and
dasatinib in vitro[15, 30, 35–39].
With the emerging interest in treating CML patients with customized therapeutic regimes,
to reduce TKI resistance and maximize treatment outcomes, there will be a need for implemen-
tation of screening procedures in order to identify patients most at risk of developing resis-
tance, thus allowing preventative clinical intervention. However, in order to determine which
patients are more likely to develop TKI resistance it is necessary to understand the kinetics of
resistance emergence. Generation of TKI-resistant cell lines via in vitro exposure to gradually
increasing concentrations of imatinib[13–16, 28, 29, 36, 39–41], nilotinib[12, 30, 41] and dasa-
tinib[15, 40] provides an experimental system resembling the in vivo situation. However, in the
majority of previous studies, resistance mechanisms were determined only once cells demon-
strated overt resistance to the end-point concentration of TKI[12, 13, 16, 28–30, 36, 39, 41, 42];
researchers did not generally examine modes of resistance in the intermediary cells created
during incremental increases of drug. Those studies that did examine the intermediate stages
of resistance focused on the generation of imatinib and dasatinib resistance only[14, 15, 35,
40]. Thus, in this study, two BCR-ABL1-expressing cell lines were cultured in increasing con-
centrations of nilotinib with samples examined at every stage of resistance generation, allowing
interrogation of resistance development dynamics.
In an in vitromodel of imatinib resistance, ABCB1 overexpression appeared most relevant
during early stages of resistance development[40]. Thus, we postulated that increased ABCB1,
leading to reduced intracellular levels of TKI, created a favorable environment for development
of additional resistance mechanisms. In addition to the two nilotinib resistant cell lines gener-
ated as part of the current study, we also had access to imatinib- and dasatinib-resistant cells
previously generated in our laboratory. In this prior study, kinase domain mutations and
BCR-ABL overexpression were identified as end-point resistance mechanisms, however,
ABCB1 expression was not examined over the course of resistance generation[15]. In the cur-
rent study we now investigate the kinetics of ABCB1 expression and thus are able to evaluate
the interplay of ABCB1 expression and secondary resistance mechanisms in vitro across three
FDA approved TKIs. Additionally, in vivo evidence from two separate studies suggest that
ABCB1 overexpression may also precede mutation development, disease progression and treat-
ment failure in patients undergoing imatinib therapy[43–45]. Taken together, these results
support ABCB1 overexpression as a likely initiator of resistance to imatinib, nilotinib and dasa-
tinib and provide a strong rationale for investigations into the use of ABCB1 as a prognostic
biomarker for identification of patients likely to respond poorly to TKI therapy.
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BCR-ABL1-expressing cell lines K562 (American Type Culture Collection (ATCC) Manassas,
VA, USA) and the ABCB1 overexpressing variant, K562-Dox, (Leonie Ashman, University of
Newcastle, Callaghan, NSW) were cultured as described previously[46]. K562-Dox cells stably
overexpress ABCB1 as a result of long-term exposure of the parental K562 cell line to the
ABCB1 substrate doxorubicin.
Generation of TKI-resistant cell lines
Cell lines maintained in liquid culture were gradually exposed to escalating concentrations of
nilotinib (Tasigna; kindly provided by Novartis Pharmaceuticals, Basel, Switzerland) as
described in Supplemental methods. In washout experiments, cells were washed 3× in drug
free media, left to equilibrate overnight, washed 3× in drug free media and cells lysed. Control
cell lines cultured in 0.1% DMSO were maintained in parallel. Imatinib and dasatinib resistant
cells were generated and cultured as described previously[15].
IC50 assays and western blotting
2×105 BCR-ABL1-expressing cells were incubated for 2 h at 37°C/5%CO2 with concentrations
of nilotinib ranging 0–100 μM, imatinib ranging 0–100 μM and dasatinib ranging 0–5000 nM.
Following incubation, cells were lysed in Laemmli’s buffer[47] before resolution by 12%
SDS-PAGE and electrophoretic transfer to PVDF membrane (GE Healthcare, Buckingham-
shire, UK) at 65 mA overnight. Western blotting for phosphorylated CT10 regulator of kinase
like (p-CRKL) was performed as previously described[48]. IC50 values were determined as the
dose of drug required to reduce p-CRKL levels by 50% and are presented as mean ± SEM.
Cyclosporine A (Sigma-Aldrich, St. Louis, MO, USA) is an inhibitor of ABCB1 and was used at
10 μM; PSC-833 is a cyclosporine A derivative kindly provided by Novartis Pharmaceuticals
and was used at 10 μM.Western blotting for other proteins was performed as described in Sup-
plemental methods.
Cell viability assays
Cells were washed and resuspended in fresh culture media before culture in 24-well plates
(Thermo Fisher Scientific, Waltham, MA, USA) in the presence of TKI at a density of 2×105
cells/mL. Plates were seeded with 1 mL of cell suspension in triplicate, placed in sterilised con-
tainers and incubated for 72 h before cell viability determination with 7-aminoactinomycin D
(7-AAD; Invitrogen Life Technologies, Carlsbad, CA, USA) and Phycoerythrin (PE)-conju-
gated Annexin V antibody (BD Biosciences, Franklin Lakes, NJ, USA). Flow cytometric analy-
sis was conducted with an FC500 flow cytometer (Beckman Coulter, Miami, FL, USA) and
FCS Express 4 software (De Novo Software, Los Angeles, CA, USA).
Flow cytometry and fluorescent substrate efflux studies
ABCB1 cell surface expression and function was measured as described previously[46]. Mean
Fluorescence Intensity was used to calculate fold changes in ABCB1 expression in resistant vs.
control cells.
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Real time quantitative polymerase chain reaction (RQ-PCR)
1×107 intermediately resistant cells were stored in TRIzol stabilization solution (Invitrogen
Life Technologies) at -80°C. RNA was extracted using the phenol/chloroform method[49] and
cDNA synthesized using random hexamers (GeneWorks, Hindmarsh, SA, Australia) and
Superscript II reverse transcriptase (Invitrogen Life Technologies). Primers were designed
using Primer Express software v2.0 (Applied Biosystems, Foster City, CA, USA), and sequences
were as described in Supplemental methods. Amplification was performed using RT2 real-time
SYBR Green/ROX PCR Master Mix (SuperArray Bioscience, Frederick, MD, USA) on a Rotor-
Gene real time PCR machine (Corbett Research, San Francisco, CA, USA). Results were ana-
lysed using Rotor-Gene 6000 Series software (Corbett Research) and the relative expression
levels of the genes of interest were calculated by the comparative Ct method using the 2ΔΔCt for-
mula to achieve results for relative quantification. Control cell lines were used as calibrators
and all samples were normalized to house keeping genes (BCR for ABCB1, GUSB for LYN).
BCR-ABL1 quantitation and mutation analysis
BCR-ABL1mRNA expression levels were quantitated using the TaqMan Universal PCRMas-
ter Mix (Applied Biosystems) and the ABI Prism 7500 Sequence Detection System (Applied
Biosystems) as described previously[15]. BCR-ABL1 kinase domain sequencing was performed
as described previously[15].
Statistics
Statistical tests were performed using the GraphPad Prism 5 statistical software (GraphPad
Prism Inc, La Jolla, CA, USA). Normality tests were performed on each data set using the
D’Agostino & Pearson omnibus normality test. The Mann-Whitney Rank Sum or the Student’s
t-test were used to determine differences between experimental groups depending on whether
the data sets failed or passed the normality test, respectively. Differences were considered to be
statistically significant when the probability value (p-value) was<0.05.
Results
Generation of nilotinib resistant cells lines
Nilotinib resistant K562 and K562-Dox (ABCB1 overexpressing) cells were generated; nilotinib
concentrations up to 100 nM were easily tolerated, however, upon exposure to 125 nM niloti-
nib, cell growth stalled and viability significantly decreased (S1 Table). After prolonged expo-
sure to 125 nM nilotinib (K562 nilotinib intermediate #6), cell viability increased to ~80% and
resistance to nilotinib was evaluated by IC50 based on p-CRKL protein expression. These
assays rely on BCR-ABL kinase inhibition as the key readout and thus enable a distinction
between BCR-ABL dependent and BCR-ABL independent resistance; an increase in IC50 value
indicates on target, BCR-ABL dependent resistance. K562 #6 NIL cells demonstrated signifi-
cantly increased IC50NIL when compared with control cells (2066 nM vs. 199 nM, p<0.001; Fig
1A, S1A Fig). Resistance was confirmed by cell viability assays (87% vs. 19% survival in 1000
nM nilotinib, p<0.001; Fig 1A). K562 #6 NIL cells were assessed for resistance to imatinib and
dasatinib and again demonstrated significantly increased IC50 when compared with control
cells (20.5 μM vs. 3.3 μM, p = 0.004 and 11.7 nM vs. 5.6 nM, p<0.001 for imatinib and dasati-
nib respectively; Fig 1B and 1C, S1B and S1C Fig). These results were confirmed by cell viability
assays (92% vs. 29% in 5 μM imatinib and 74% vs. 21% in 500 nM dasatinib, p<0.001; Fig 1B
and 1C).
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Fig 1. K562 and K562-Dox cells cultured long term in nilotinib demonstrate cross-resistance to imatinib and dasatinib. (a-c) K562 and (d-f)
K562-Dox cells were incubated for 3 days with the indicated concentrations of (a,d) nilotinib, (b,e) imatinib or (c,f) dasatinib. Cell viability was determined by
Annexin V/7-aminoactinomycin D staining in at least three independent experiments and expressed as %live cells (line graphs). p-CRKL dependent IC50
(dose of TKI required to reduce p-CRKL levels by 50%) was calculated by western blot in at least three independent experiments. Average IC50 values of the
corresponding densitometry analyses are denoted in the column graphs. Representative western blots are shown in S1 Fig. Cell viability statistical analyses
compared% live cells at common TKI concentrations; western blot statistical analyses compared resistant cells to corresponding controls. Analyses were
performed using unpaired Student’s t-test (Welch’s correction was applied for data groups with unequal SD) or Mann-Whitney Rank Sum test. Statistically
significant p-values are denoted by carets (^) or asterisks (* p<0.05; ** p<0.01; *** p<0.001). Error bars represent SEM. NIL = nilotinib.
doi:10.1371/journal.pone.0161470.g001
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In order to replicate the in vivo concentration of nilotinib to which a patient’s leukemic cells
are exposed[50], K562 #6 NIL cells were cultured in increasing concentration of nilotinib for a
further two months until a concentration of 2 μM nilotinib was reached. Once this concentra-
tion was tolerated, the resultant K562 #10 NIL cells were assessed for maintenance of resistance
compared with control cells (IC50NIL = 1661 nM; 85% survival in 1000 nM nilotinib, p<0.001
for all nilotinib concentrations; Fig 1A). K562 #10 NIL cells also maintained resistance to ima-
tinib (IC50IM = 21.2 μM, 89% survival in 5 μM imatinib, p<0.001; Fig 1B) and dasatinib
(IC50DAS = 7.6 nM, p = 0.038; 74% survival in 500 nM dasatinib, p<0.001; Fig 1C). Thus the
generation of nilotinib resistance in K562 led to a pan-resistant phenotype in all cases.
Development of nilotinib resistance was also evaluated in the setting of ABCB1 overexpres-
sion (S1 Table): K562-Dox #5 NIL cells demonstrated significantly increased survival com-
pared with control cells (74% vs. 8% survival in 1000 nM nilotinib, p<0.001; Fig 1D). Similar
results were observed for imatinib (79% vs. 31% survival in 5 μM imatinib, p = 0.014; Fig 1E)
and dasatinib (60% vs. 5% survival in 100 nM dasatinib, p<0.001; Fig 1F). Analogous levels of
resistance were observed for K562-Dox #8 NIL cells (Fig 1D–1F).
However, when resistance to TKI was assessed by p-CRKL dependent IC50, unexpected
results were observed: IC50 to all three TKIs decreased. IC50NIL decreased from 507 nM to 219
nM (p<0.001; Fig 1D, S1D Fig); IC50IM decreased from 10.4 μM to 1.62 μM (p<0.001; Fig 1E,
S1E Fig); IC50DAS decreased from 108 nM to 13.1 nM (p<0.001; Fig 1F, S1F Fig). A further
decrease in IC50 was observed in K562-Dox #8 NIL cells despite the obvious resistance to all
three TKIs measured in cell viability assays (Fig 1D–1F, S1D, S1E and S1F Fig). Given that
p-CRKL is a downstream target of BCR-ABL, a decrease in IC50 indicated that these cells had
developed a BCR-ABL independent mechanism of resistance.
ABCB1 overexpression is the initiator of resistance to nilotinib in vitro
Once overt TKI resistance had been established, potential mechanisms of resistance were interro-
gated. Due to the likelihood of ABCB1 involvement in nilotinib transport[34], ABCB1 protein
and mRNA expression was monitored over the course of resistance development. The onset of
resistance within K562 #6 NIL cells coincided with a significant increase inABCB1mRNA
expression: resistant cells demonstrated up to 4.7-fold greater levels of ABCB1mRNA compared
with control cells (p<0.01; Fig 2A). Surface ABCB1 protein expression was also significantly
increased in K562 #6 NIL cells compared with control (up to 56% ABCB1 vs. 8%; p = 0.002).
However, upon continued culture to 2 μM nilotinib (intermediate #10), both ABCB1 mRNA and
protein expression reduced to levels comparable with that of control cells (Fig 2A).
In order to determine whether increased expression of ABCB1 had a direct impact on
nilotinib resistance, p-Crkl dependent IC50NIL experiments were performed in the pres-
ence and absence of two ABCB1 inhibitors (cyclosporine and PSC-833). Indeed, a signifi-
cant reduction in IC50NIL was observed in resistant cells in the presence of both inhibitors:
K562 #6 NIL IC50NIL reduced from 2066 nM to 1522 nM in the presence of cyclosporine
(p = 0.043) and to 1155 nM in the presence of PSC-833 (p = 0.009). No significant effect of
ABCB1 inhibition on IC50NIL was observed in K562 control cells (Fig 3). Interestingly,
even in the presence of complete ABCB1 inhibition, the IC50NIL of K562 #6 NIL cells
remained significantly increased compared with K562 control cells indicating the presence
of an additional resistance mechanism in this cell line. Further evidence for the direct
involvement of ABCB1 overexpression in nilotinib resistance was provided when IC50NIL
was examined over a seven-day period in K562 #6 NIL cells overexpressing ABCB1.
During this time period, ABCB1 expression decreased from 85% to 72% to 61% with a cor-
responding decrease in IC50NIL from 2700 nM to 2120 nM to 1570 nM (S2 Fig). Taken
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together, these data indicate a key role for ABCB1 overexpression in the nilotinib resistance
observed in this cell line model.
The phenomenon of initial ABCB1 overexpression followed by a significant reduction to
almost negligible levels was also observed during development of TKI resistance in
K562-Dox cells; an intriguing observation given that this cell line has stably expressed
ABCB1 for over a decade. Initially, elevated expression of both ABCB1mRNA (3.5-fold
increase, p = 0.002) and protein (MFI 487 vs. 213, p<0.001) was observed when compared
with levels in K562-Dox control cells (Fig 2B). However, upon prolonged culture (when cell
growth stalled and viability decreased, S1 Table) two populations of cells became apparent,
an ABCB1-positive population and an ABCB1-negative population. Interestingly, the
Fig 2. Onset of nilotinib resistance in K562 and K562-Dox cells coincides with ABCB1 overexpression; ABCB1 levels decrease upon continued
high dose nilotinib exposure. Expression levels of ABCB1mRNA/protein were assessed in (a) K562 and (b) K562-Dox nilotinib resistant cells. K562 cells
were also assessed for LYNmRNA expression. mRNA expression represents the mean of six independent experiments performed in triplicate. The
histograms shown are representative of typical protein expression levels. The blue and black lines represent resistant and control cells respectively, the grey
filled histograms represent cells stained with isotype control and percentage of cells staining positive for ABCB1 expression is indicated (c) K562-Dox cells
were stained with the fluorescent ABCB1 substrate rhodamine-123 and assessed for their ability to effectively efflux rhodamine-123 in the absence and
presence of the specific ABCB1 inhibitor PSC-833. K562 cells were used as a negative control for ABCB1 efflux. The histograms shown are representative of
typical efflux patterns. The black lines represent fluorescent substrate alone while the blue lines represent PSC-833 mediated inhibition of ABCB1. Statistical
analyses compared mRNA levels (as a percentage of house keeping genes) in each resistant intermediate to control cells. Analyses were performed using
unpaired Student’s t-test (Welch’s correction was applied for data groups with unequal SD) or Mann-Whitney Rank Sum test. Statistically significant p-values
are denoted by carets (^) or asterisks (* p<0.05; ** p<0.01; *** p<0.001). Error bars represent SEM. NIL = nilotinib.
doi:10.1371/journal.pone.0161470.g002
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ABCB1-negative population increased correspondingly with time in culture (S3 Fig) suggest-
ing that those cells with decreased ABCB1 expression had a growth advantage and were
clonally selected over time. Following continued escalation of nilotinib to 2 μM (#8 NIL resis-
tance intermediate), ABCB1 mRNA and protein expression was negligible and comparable
to levels observed in parental K562 cells (Fig 2B).
Fig 3. Inhibition of ABCB1 significantly reduces resistance in ABCB1 overexpressing K562 cells. p-CRKL dependent IC50 (dose of TKI required to
reduce p-CRKL levels by 50%) was calculated by western blot in at least four independent experiments with the average IC50 values from the resultant
densitometry analyses denoted by the columns. Statistical analyses compared resistant cells in the presence vs. absence of ABCB1 inhibition (asterisks)
and also resistant cells in the absence and presence of ABCB1 inhibitors with control cells in the absence of inhibitor (carets). Analyses were performed
using unpaired Student’s t-test (Welch’s correction was applied for data groups with unequal SD) or Mann-Whitney Rank Sum test. Statistically significant p-
values are denoted by carets (^) or asterisks (* p<0.05; ** p<0.01; *** p<0.001). Error bars represent SEM. NIL = nilotinib; cyclo = cyclosporine;
PSC = PSC-833.
doi:10.1371/journal.pone.0161470.g003
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K562-Dox cells lose all functional ABCB1 following continued culture in
nilotinib
To our knowledge this is the first report documenting loss of ABCB1 expression in K562-Dox
cells due to continued culture in TKI. Thus, it was important to determine whether there was
also loss of ABCB1 function. Therefore, K562-Dox #8 NIL cells were assessed for ability to
effectively efflux the ABCB1 substrate rhodamine-123. Results demonstrated a complete loss of
ABCB1 function with the resistant cell line demonstrating comparable rhodamine-123 levels
to the parental K562 cell line. Rhodamine-123 levels in K562-Dox control cells were as
expected (Fig 2C).
ABCB1 overexpression precedes increased LYN phosphorylation in
nilotinib resistant K562 cells
Because BCR-ABL1 overexpression is a common form of TKI resistance observed in patients
[21], resistant K562 cells were screened for increased expression of BCR-ABL protein. Results
demonstrated this possibility unlikely since no overexpression or increased kinase activity (as
measured by phospho-BCR-ABL) was observed in early or late stage resistance intermediates
(Fig 4A). No kinase domain mutations were detected in any K562 resistance intermediates (S1
Appendix). Overexpression/increased activity of LYN was also investigated: results demon-
strated increased LYNmRNA in K562 #6 NIL cells that remained high for the duration of
nilotinib escalation (15–18 fold increase compared with control cells, p<0.05; Fig 2A). Addi-
tionally, catalytic activation of LYN increased significantly as measured by autophosphoryla-
tion at tyrosine 396 (Y396, p = 0.008; Fig 4B).
ABCB1 overexpression precedes Bcr-Abl independent resistance in
nilotinib resistant K562-Dox cells
BCR-ABL kinase activity was assessed in nilotinib resistant K562-Dox cells to confirm ade-
quate inhibition of phosphorylation. Nilotinib was removed from K562-Dox #8 NIL culture
media by thorough washing followed by overnight equilibration. Total and phospho-BCR-ABL
levels were determined and compared with the levels in cells that remained in continuous cul-
ture with nilotinib. Results demonstrated complete inhibition of kinase activity in the presence
of nilotinib. However, upon drug washout, reactivation of BCR-ABL occurred resulting in sim-
ilar levels of phospho-BCR-ABL in both resistant and control cells (p>0.05). Importantly, total
BCR-ABL levels remained unaffected in the absence and presence of nilotinib (Fig 4C). Thus,
while nilotinib was effective at inhibiting BCR-ABL kinase activity, cells demonstrated com-
plete resistance indicating the presence of an independent resistance mechanism. Additionally,
no increase in LYN expression or activity was observed (S4 Fig); in fact, resistant cells demon-
strated significantly decreased levels of LYN compared with control cells excluding LYN as a
likely effector of resistance as has previously been reported[30, 41].
ABCB1 overexpression precedes resistance to imatinib and dasatinib in
vitro
Given that ABCB1 is likely to play a role in the transport of, and resistance to, imatinib and
dasatinib[34], ABCB1 expression was examined in previously established imatinib and dasati-
nib resistant cell lines and correlated with already defined mechanisms of resistance[15].
Indeed, ABCB1mRNA expression increased initially in response to both imatinib and dasati-
nib exposure, and then decreased once further resistance mechanisms predominated. When
compared with control cells, imatinib-resistant K562 cells demonstrated up to 2.8-fold greater
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levels of ABCB1mRNA; a significant decrease in expression of ABCB1mRNA was associated
with an increase in LYNmRNA expression (Fig 5A). Similarly, a peak of 8.6-fold greater
ABCB1mRNA levels in KU812 imatinib resistant cells was observed prior to a concomitant
Fig 4. Nilotinib resistant K562 cells exhibit increased activity of LYN kinase. Expression levels of total and phospho (a,c) BCR-ABL and (b) LYN were
assessed during development of nilotinib resistance in (a,b) K562 and (c) K562-Dox cells. Protein levels were normalised to β-ACTIN and levels in nilotinib
resistant intermediates were then compared to levels in control cells. The western blot analyses are representative and the corresponding densitometry
analyses represent the mean of at least three experiments. Statistical analyses compared resistant cells to corresponding controls. Analyses were performed
using unpaired Student’s t-test (Welch’s correction was applied for data groups with unequal SD). Statistically significant p-values denoted by asterisks
(* p<0.05; ** p<0.01). Error bars represent SEM. NIL = nilotinib.
doi:10.1371/journal.pone.0161470.g004
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decrease in expression following development of the imatinib resistant F359C kinase domain
mutation (Fig 5B). The same initial increase in ABCB1mRNA followed by a decrease once
additional resistance mechanisms predominated was observed in two separate dasatinib resis-
tant K562-Dox cell lines (DAS1 and DAS2; Fig 5C and 5D). ABCB1 protein expression con-
firmed these data (S5 Fig). Taken together, these results indicate that ABCB1 overexpression
likely acts as an initial mediator of resistance to nilotinib, imatinib and dasatinib providing
favourable conditions for further resistance development.
Discussion
Nilotinib-resistant cell lines have previously been generated as a means of recapitulating in vivo
resistance, however, this is the first study in which the resistance mechanisms were studied in a
sequential fashion to better define the dynamics of resistance development. The model described
here allowed an interrogation of the interplay between various mechanisms in the development
of frank resistance. In addition, previous studies have generated cells resistant to 20 nM[30] and
50 nM[12] nilotinib whereas the end-point concentration of nilotinib chosen in this study (2 μM)
better reflects the trough plasma level observed in patients[50] and thus is a more accurate repre-
sentation of the nilotinib concentration to which a patient’s leukaemic cells are exposed.
Even though TKIs such as imatinib, and more recently nilotinib and dasatinib, have resulted
in significantly better treatment outcomes for the majority of patients with CML, resistance to
Fig 5. ABCB1mRNA levels increase initially in imatinib and dasatinib resistant cell lines but decrease following emergence of additional
resistance mechanisms. Expression levels of ABCB1mRNA were assessed in (a) K562, (b) KU812 and (c, d) K562-Dox cells resistant to (a, b) imatinib or
(c, d) dasatinib. Expression levels were then correlated with other, previously defined, resistance mechanisms denoted by red and blue lines[15].
Specifically, (a) LYNmRNA expression, % of (b) imatinib resistant (F359C) and (c) dasatinib resistant (V299L) kinase domain mutations, (d) BCR-ABL1
mRNA expression. ABCB1mRNA expression represents the mean of at least four independent experiments performed in triplicate. Statistical analyses
compared mRNA levels (as a percentage of house keeping genes) in each resistant intermediate to corresponding control cells. Analyses were performed
using unpaired Student’s t-test (Welch’s correction was applied for data groups with unequal SD) or Mann-Whitney Rank Sum test. Statistically significant p-
values are denoted by carets (^) or asterisks (* p<0.05; ** p<0.01). Error bars represent SEM. IM = imatinib; DAS = dasatinib.
doi:10.1371/journal.pone.0161470.g005
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therapy is still a problem for a significant proportion of patients (up to 30%)[8, 9]. Addition-
ally, BCR-ABL independent mechanisms of resistance are poorly understood. Accordingly, a
greater understanding of the kinetics of resistance development, especially in the BCR-ABL
independent setting, is required. As we move into the era of customised treatment regimes, it
becomes important to predict which patients are likely to respond to a given TKI such that
treatment plans are tailored to the individual. Thus, in vitro cell line models are key in deter-
mining, not only common modes of TKI resistance, but also kinetics of resistance develop-
ment. In this study, two cell line models of nilotinib resistance were generated and resistance
emergence examined; resistance kinetics in response to imatinib and dasatinib were assessed in
four additional cell lines. Results highlighted ABCB1 overexpression as a likely initiator of
resistance to all three TKIs.
Notably, this is the first report of ABCB1 overexpression in the K562 cell line in response to
exposure to nilotinib, which decreased following a concordant increase in LYN kinase activity.
LYN overexpression has previously been reported as a BCR-ABL independent mode of resis-
tance[27]. However, in the current study, K562 #10 NIL cells with increased LYN activity also
demonstrated increased p-CRKL dependent IC50, which was unexpected if the resistance was
BCR-ABL-independent. This, combined with the fact that LYN reportedly regulates BCR-ABL
activity[33, 51, 52], suggests that LYN overexpression is in fact a BCR-ABL dependent mecha-
nism of resistance, which challenges current dogma. More intriguing is the fact that these cells
remain resistant to dasatinib, which has activity against Src Family Kinases including Lyn. This
raises the possibility that an additional resistance mechanism/s is present (eg: overexpression
of an efflux transporter, activation of an alternate signalling pathway) and warrants further
investigation.
Exposure of K562-Dox cells to nilotinib resulted in a complete loss of ABCB1 expression
and function following initial ABCB1 overexpression. K562-Dox cells have stably expressed
ABCB1 for over a decade and this is the first report of complete loss of ABCB1 expression back
to levels observed in parental K562 cells. No overexpression or increased activity of LYN was
observed. Instead, resistance is likely attributable to a novel BCR-ABL independent mechanism
of resistance, an area of research under current investigation.
Examination of imatinib- and dasatinib-resistant cell lines generated within our laboratory
and characterised previously[15] also highlighted ABCB1 overexpression as an initiating
mechanism of resistance to these TKIs. Again, most previous studies examined resistance in
cells surviving end-point TKI concentration only[12, 13, 16, 28–30, 36, 39, 41, 42]. Two studies
in which intermediately resistant cells were studied either failed to examine ABCB1 expression
[14], or did not correlate the increased ABCB1 expression observed with TKI resistance[35].
One recent study, however, did confirm our findings with results demonstrating exposure of
K562 cells lines to imatinib and dasatinib resulted in increased ABCB1mRNA. Authors also
hypothesised that increases in transporter expression may be important in the early stages of
resistance development but not as crucial after prolonged exposure to TKI[40]. The involve-
ment of ABCB1 in development of resistance to nilotinib, imatinib and dasatinib is further sub-
stantiated when the rate of resistance acquisition in K562-Dox cells, which already overexpress
ABCB1, is considered. When compared with K562 and KU812 cells (which express negligible
basal levels of ABCB1) K562-Dox cells develop resistance to nilotinib, imatinib and dasatinib
at a faster rate, withstanding higher concentrations of TKIs earlier in the dose escalation pro-
cess. K562-Dox cells also required less time to tolerate a given concentration of TKI, reaching
end point concentrations faster. These data confirm ABCB1 overexpression as a key initiator
of resistance to all three TKIs (S2 Table). Thus, it appears likely that ABCB1 overexpression
causes increased export of TKIs leading to lower intracellular concentrations. This then results
in suboptimal BCR-ABL inhibition, which presumably creates a favourable environment for
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development of other more efficient resistance mechanisms. Given the variety of resistance
mechanisms observed, both in our studies and those from others, it is likely that the events fol-
lowing ABCB1 up regulation, are stochastic in nature and dependent on the cell lines studied.
In conclusion, the findings detailed here suggest that ABCB1 overexpression likely provides
an initial platform required for development of additional mechanisms of resistance to TKIs in
vitro. The cell line models of resistance described provide a valuable tool for studying resistance
in patients. We observed a consistent upregulation of ABCB1 as a result of exposure to three
FDA approved TKIs; we are currently investigating whether this phenomenon also occurs in
patients receiving TKI therapy. With further in vivo validation, the results presented here sug-
gest monitoring of ABCB1 levels may potentially identify patients likely to develop additional
resistance and/or respond poorly to their current therapy regime.
Supporting Information
S1 Appendix. K562 nilotinib resistance intermediates do not harbour any Bcr-Abl kinase
domain mutations. DNA sequencing of the Bcr-Abl kinase domain of K562 control cells and
nilotinib 4resistance intermediates was conducted and compared with the GenBank ABL refer-
ence sequence. Data demonstrate that neither the control cells nor any of the resistance inter-
mediates contain mutations. Data were analysed using Mutation Surveyor Version 3.24 with
each peak representing a DNA base (A = Adenine; C = Cytosine; G = Guanine; or
T = Thymine) in the 5’-3’ direction of the ABL sequence. The base number for both the refer-
ence sequence and the sequences of interest are indicated. The amino acid and corresponding
residue number are also indicated. The amino acid sequences exactly match the reference
sequence with no kinase domain mutations present. NIL = nilotinib.
(PDF)
S1 Fig. K562 and K562-Dox cells cultured long term in nilotinib demonstrate cross-resis-
tance to imatinib and dasatinib. (a-c) K562 and (d-f) K562-Dox cells were incubated with the
indicated concentrations of (a,d) nilotinib, (b,e) imatinib or (c,f) dasatinib. CRKL western
blotting was performed to determine the concentration of TKI required for 50% BCR-ABL
kinase inhibition. The western blot analyses are representative and the arrows indicate approxi-
mate IC50. NIL = nilotinib; IM = imatinib; DAS = dasatinib.
(TIF)
S2 Fig. ABCB1 expression levels directly influence IC50NIL in nilotinib resistant K562 cells.
p-CRKL dependent IC50 (dose of TKI required to reduce p-CRKL levels by 50%) was deter-
mined three separate times over a period of seven days; ABCB1 expression was simultaneously
determined. The western blot analyses shown represent a single experiment with the Image-
Quant densitometry analyses depicted underneath. The boxes around the 1500 nM nilotinib
western bands highlight the clear difference in %p-CRKL likely attributable to the level of
ABCB1 expression. The percentages displayed in the histograms denote cells positive for
ABCB1 expression. The bold blue and black lines represent resistant and control cells respec-
tively, stained with ABCB1 antibody while the grey filled histograms represent cells stained
with isotype control antibody.
(TIF)
S3 Fig. Two populations of K562-Dox cells (ABCB1 positive and ABCB1 negative) arise
following prolonged culture in nilotinib. Expression levels of ABCB1 protein were assessed
in K562-Dox #5 NIL cells over a period of two months compared with that in control cells. The
histograms shown are representative of typical expression levels. The blue and black lines rep-
resent resistant and control cells respectively, the grey filled histograms represent cells stained
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with isotype control.
(TIF)
S4 Fig. There is no increase in LYN expression or activity in K562-Dox cells suggesting
BCR-ABL independent resistance to nilotinib. (a) mRNA and (b) protein expression levels
for LYN kinase were assessed during development of nilotinib resistance in K562-Dox cells.
mRNA expression represents the mean of at least three independent experiments performed in
triplicate. Western blot analyses shown are representative with the corresponding quantitation
representing the mean of three experiments. mRNA levels were normalised to GUSB, protein
levels were normalised to β-ACTIN. Statistical analyses were performed using unpaired Stu-
dent’s t-test with statistically significant p-values denoted by asterisks ( p<0.01; 
p<0.001). Error bars represent SEM. NIL = nilotinib.
(TIF)
S5 Fig. ABCB1 protein levels increase initially in imatinib and dasatinib resistant cell lines
but decrease following emergence of predominating resistance mechanisms. Expression levels
of ABCB1 protein were assessed in (a) K562 (b) KU812 (c, d) K562-Dox cells cultured in increas-
ing concentrations of (a,b) imatinib and (c,d) dasatinib and compared with levels in correspond-
ing control cells. The histograms shown are representative of typical expression levels with the
MFI indicated. The blue and black lines represent resistant and control cells respectively, the grey
filled histograms represent cells stained with isotype control. IM = imatinib; DAS = dasatinib.
(TIF)
S6 Fig. ABCB1mRNA levels increase initially in imatinib resistant KU812 cells then
decrease following emergence of kinase domain mutations. Expression levels of ABCB1
mRNA were assessed in KU812 cells resistant to imatinib. Expression levels were then corre-
lated with other, previously defined, resistance mechanisms[15]. Specifically, % of BCR-ABL1
mRNA (maroon line) and % of various kinase domain mutations (orange, yellow, green, blue,
purple lines) are indicated. mRNA expression represents the mean of at least three independent
experiments performed in triplicate. Error bars represent SEM. IM = imatinib.
(TIF)
S1 Table. Summary of nilotinib (NIL) concentrations to which cell line resistance interme-
diates were exposed and the corresponding number of days before dose was increased.
(DOCX)
S2 Table. Summary of imatinib (IM) and dasatinib (DAS) concentrations to which cell line
resistance intermediates were exposed and the corresponding number of days before dose
was increased. Cells lines shown in bold have been assessed for ABCB1 expression in the cur-
rent manuscript. Note that cell lines expressing negligible levels of ABCB1 (K562 and KU812)
required longer periods of time to develop resistance to IM and DAS compared with
K562-Dox cells which demonstrate overexpression of ABCB1 initially. Additionally, genera-
tion of a DAS resistant K562 cell line was extremely difficult (cells kept dying at the 1 nM DAS
stage, intermediate #2) and was attempted three times before successful dose escalation
occurred. A DAS resistant KU812 cell line could not be generated due to the inherent sensitiv-
ity to TKIs of this cell line.
(DOCX)
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